Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: A pilot study.

Clinical Neurology and Neurosurgery
Giulia AlessandriaFabio Bandini

Abstract

Moderate to severe spasticity is commonly reported in Multiple Sclerosis (MS) and its management is still a challenge. Cannabinoids were recently suggested as add-on therapy for the treatment of spasticity and chronic pain in MS but there is no conclusive scientific evidence on their safety, especially on cognition and over long periods. The aim of this prospective pilot study was to assess the long-term effects of a tetrahydrocannabinol-cannabidiol (THC/CBD) oromucosal spray (Sativex®) on cognition, mood and anxiety. An extensive and specific battery of neuropsychological tests (Symbol Digit Modalities Test-SDMT, California Verbal Learning Test-CVLT, Brief Visuospatial Memory Test-BVMT; PASAT-3 and 2; Free and Cued Selective Remind Test-FCSRT, Index of Sensitivity of Cueing-ISC) was applied to longitudinally investigate different domains of cognition in 20 consecutive MS patients receiving Sativex for spasticity. The primary endpoint was to assess any variation in cognitive performance. Secondary outcomes regarding mood and anxiety were investigated by means of Beck Depression Inventory (BDI) and Hamilton Anxiety Rating Scale (HAM-A). Any change in patients' spasticity was evaluated using the 0-10 Numerical Rating Scale (NRS)....Continue Reading

References

Oct 1, 1992·Brain : a Journal of Neurology·A FeinsteinM Ron
Nov 1, 1984·Journal of Clinical Neuropsychology·H Buschke
Jun 1, 1993·Brain : a Journal of Neurology·A FeinsteinA Thompson
Feb 28, 2003·The Clinical Neuropsychologist·Ralph H B BenedictFrederick Munschauer
Jan 1, 1959·The British Journal of Medical Psychology·M HAMILTON
Jun 1, 1961·Archives of General Psychiatry·A T BECKJ ERBAUGH
Jun 9, 2004·Neurology·A J ClarkM E Lynch
Oct 9, 2004·Multiple Sclerosis : Clinical and Laboratory Research·M A RizzoT L Vollmer
Sep 20, 2006·Journal of the International Neuropsychological Society : JINS·Ralph H B BenedictBianca Weinstock-Guttman
Feb 14, 2007·Multiple Sclerosis : Clinical and Laboratory Research·B A ParmenterR H B Benedict
Jan 1, 2008·Current Drug Abuse Reviews·Nadia Solowij, Robert Battisti
Dec 3, 2009·The Clinical Neuropsychologist·Shane StegenRalph H B Benedict
Feb 18, 2011·CNS Drugs·John P Zajicek, Vicentiu I Apostu
Mar 3, 2011·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A NovotnaUNKNOWN Sativex Spasticity Study Group
Mar 10, 2011·Annals of Neurology·Chris H PolmanJerry S Wolinsky
May 20, 2011·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·P FrassonF Clerici
Jul 15, 2011·Arquivos de neuro-psiquiatria·Joseph Bruno Bidin BrooksYara Dadalti Fragoso
Aug 11, 2012·Journal of Neurology·Michael G SerpellChristine Collin
Nov 28, 2012·Journal of Neurology·Maria Pia AmatoGiancarlo Comi
Jan 25, 2014·European Neurology·Tiina Rekand
Aug 5, 2015·Journal of Neurology·G CogheE Cocco
Sep 27, 2015·Handbook of Experimental Pharmacology·Gareth Pryce, David Baker
May 10, 2017·Nature Medicine·Andras Bilkei-GorzoAndreas Zimmer
Mar 27, 2018·European Journal of Clinical Investigation·Edward J Calabrese, Alberto Rubio-Casillas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cannabis & Cognition

The effect of cannabis on cognitive functioning is being explored for short and long-term effects. Recent studies have shown conflicting results, with some showing no significant effects and others showing neuropsychological impairment. Discover the latest research on cannabis and cognition here.